Etiology, clinical features and prognosis in secondary amenorrhea.
A clinical investigation of 356 patients with secondary amenorrhea revealed that 95% of patients with postpill amenorrhea and 56% of patients with anorexia nervosa recovered in 6 years. The corresponding recovery rates for patients with psychogenic amenorrhea and amenorrhea following self-induced weight loss were 72% for both groups, and in patients with the amenorrhea-galactorrhea syndrome and idiophatic functional amenorrhea the recovery rates at 6 years were 64 and 61% respectively. Unlike the other groups with functional amenorrhea, patients with the amenorrhea-galactorrhea syndrome had impaired ovarian responsiveness to exogenous gonadotropins. Bromocriptine treatment resulted in disappearance of the galactorrhea and restoration of the menses and/or ovulation in nine of 18 patients; of these three became pregnant. The effect of bromocriptine did not persist for long after treatment ceased, and permanent recovery was recorded only in four patients. The group with functional amenorrhea included 34 patients who wished to become pregnant. Gonadotropin treatment was successful in 20 patients, clomiphene-hCG in two, tamoxifen in two, bromocriptine in two, and combined bromocriptine and clomiphene in one. Thus, the overall pregnancy rate in patients with functional amenorrhea was 79%. The groups with ovarian amenorrhea inclutients with assumed ovarian failure responded to large doses of exogenous gonadotropins by ovulation and three became pregnant. Ovarian wedge resection was ineffective in all five cases with polycystic ovaries, but two patients became pregnant after treatment with clomiphene and chorionic gonadotropin, and one with exogenous gonadotropins.
D000568:Amenorrhea / Q000188:drug therapy / Q000209:etiology; D000856:Anorexia Nervosa; D001835:Body Weight; D001971:Bromocriptine / Q000627:therapeutic use; D002996:Clomiphene / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D004970:Estrone / Q000627:therapeutic use; D005260:Female; D006062:Gonadotropins / Q000627:therapeutic use; D006801:Humans; D010062:Ovulation Induction; D011372:Progestins / Q000627:therapeutic use; D011379:Prognosis
D004967:Estrogens; D006062:Gonadotropins; D011372:Progestins; D002996:Clomiphene; D004970:Estrone; D001971:Bromocriptine